Grapiprant (Galliprant)

Grapiprant, sold under the brand name Galliprant, represents an innovative approach to managing pain and inflammation in dogs with osteoarthritis. Unlike traditional nonsteroidal anti-inflammatory drugs that work by broadly inhibiting cyclooxygenase enzymes, grapiprant belongs to a novel drug class called piprants, which specifically target the EP4 prostaglandin receptor. This targeted mechanism was designed to provide effective pain relief while potentially reducing some of the adverse effects associated with COX inhibition, making it an attractive option for dogs that may not tolerate traditional NSAIDs well. Since its approval by the FDA for veterinary use, Galliprant has become an important addition to the arsenal of medications available for managing canine osteoarthritis.

The mechanism of action of grapiprant differs fundamentally from that of traditional NSAIDs. Prostaglandins are signaling molecules involved in numerous physiological processes, including inflammation, pain sensation, gastrointestinal protection, and kidney function. Traditional NSAIDs reduce prostaglandin production by blocking COX enzymes, which affects all prostaglandin-mediated functions indiscriminately. Grapiprant, in contrast, allows prostaglandins to be produced normally but selectively blocks the EP4 receptor, which is primarily responsible for mediating the pain and inflammation associated with osteoarthritis. This selective approach theoretically preserves the beneficial effects of prostaglandins on the gastrointestinal tract, kidneys, and other organ systems while still providing meaningful pain relief.

Galliprant is available as flavored tablets in three strengths: 20 mg, 60 mg, and 100 mg, allowing for appropriate dosing across a wide range of dog sizes. The pork-flavored tablets are generally well-accepted by dogs, simplifying the daily administration process for owners. The medication is given once daily, which promotes consistent compliance with the treatment regimen. Grapiprant is rapidly absorbed after oral administration, reaching peak blood concentrations within approximately one hour, and begins providing relief relatively quickly. The convenience of once-daily oral dosing, combined with the novel mechanism of action, has made Galliprant a popular choice among veterinarians seeking alternatives for dogs with osteoarthritis.

As with all prescription medications, the use of grapiprant requires appropriate veterinary supervision to ensure safety and efficacy. While its targeted mechanism of action may offer theoretical safety advantages, all medications carry potential risks that must be carefully considered for each patient. Veterinarians evaluate factors such as the dog's age, weight, overall health status, concurrent medications, and the severity of osteoarthritis when determining whether grapiprant is an appropriate treatment choice. Regular monitoring during therapy allows for assessment of treatment response and early detection of any adverse effects. Dog owners play a crucial role in treatment success by administering medication as prescribed, observing their pets for any changes, and maintaining open communication with their veterinary care team.

The FDA-approved indication for grapiprant is the control of pain and inflammation associated with osteoarthritis in dogs. Osteoarthritis, also known as degenerative joint disease, is one of the most prevalent chronic conditions affecting canine patients worldwide. This progressive condition occurs when the protective cartilage that cushions the ends of bones within joints gradually deteriorates, leading to bone-on-bone contact, inflammation, pain, and reduced mobility. Osteoarthritis can affect any joint but most commonly impacts the hips, knees (stifles), elbows, and spine in dogs. The condition significantly impairs quality of life, making effective pain management essential for maintaining comfort and function in affected animals.

Grapiprant addresses the underlying inflammatory component of osteoarthritis while providing meaningful pain relief. Dogs with osteoarthritis typically experience stiffness, particularly after rest or upon rising in the morning, reluctance to climb stairs or jump, decreased activity and playfulness, difficulty assuming positions for elimination, and visible discomfort when moving. By blocking the EP4 receptor, grapiprant reduces the pain signaling and inflammatory processes that contribute to these clinical signs. Clinical studies have demonstrated that dogs receiving grapiprant show significant improvements in pain scores, mobility assessments, and owner-reported quality of life measures compared to dogs receiving placebo.

The unique mechanism of action of grapiprant makes it particularly valuable for certain patient populations where traditional NSAIDs may pose elevated risks. Dogs with histories of gastrointestinal sensitivity, those with mild kidney or liver compromise, elderly dogs with multiple concurrent health issues, or patients that have not tolerated other NSAIDs well may be candidates for grapiprant therapy. Additionally, dogs requiring long-term pain management for chronic conditions may benefit from grapiprant's targeted approach, which preserves more physiological prostaglandin functions than traditional COX inhibition. Veterinarians often consider grapiprant as a first-line option for dogs newly diagnosed with osteoarthritis or as an alternative when other treatments have proven unsuitable.

While osteoarthritis is the primary approved indication, the anti-inflammatory and analgesic properties of grapiprant have led some veterinarians to explore its use in other painful conditions. However, it is important to note that use beyond the approved indication represents off-label prescribing, which should only occur under direct veterinary supervision with appropriate patient monitoring. Unlike some NSAIDs, grapiprant is not currently approved for postoperative pain management, and its efficacy for acute inflammatory conditions has not been extensively studied. The medication's strength lies in the management of chronic osteoarthritis pain, for which it has demonstrated clear benefits in controlled clinical trials.

The selection of grapiprant over alternative pain management options involves careful consideration of multiple factors. For dogs with straightforward osteoarthritis and no contraindications to NSAID therapy, traditional NSAIDs with longer track records may be equally appropriate choices. However, grapiprant offers advantages for dogs with risk factors that make traditional NSAIDs less suitable. The relatively recent introduction of grapiprant to the veterinary market means that long-term safety data is still accumulating, but studies to date suggest a favorable safety profile. Cost considerations may also influence treatment selection, as grapiprant tends to be priced higher than some older generic NSAIDs. Ultimately, the veterinarian and owner together determine the most appropriate treatment approach based on the individual dog's needs, health status, and circumstances.

Grapiprant dosing in dogs is weight-based and must be determined by a veterinarian who has examined the patient and assessed their specific needs. Accurate body weight measurement is fundamental to appropriate dosing, as the recommended dose of grapiprant is 2 mg per kilogram of body weight (approximately 0.9 mg per pound) administered once daily. Given the significant variation in dog sizes, from tiny toy breeds to massive giant breeds, proper weight assessment ensures that each patient receives an effective dose without unnecessary risk of adverse effects. Owners should not attempt to calculate doses independently or adjust prescribed amounts without explicit veterinary guidance.

Galliprant tablets are available in 20 mg, 60 mg, and 100 mg strengths to accommodate the dosing requirements of different-sized dogs. Veterinarians select the appropriate tablet strength or combination of tablets to achieve a dose as close to the 2 mg/kg target as possible. For some dogs, particularly those at intermediate weights, achieving exact dosing may require tablet combinations or accepting a dose slightly above or below the ideal target within acceptable ranges. The scored tablets can be divided if necessary to facilitate more precise dosing, though the manufacturer's guidance should be followed regarding tablet division. Dogs weighing less than 8 pounds (3.6 kg) are below the minimum weight for which grapiprant use has been established.

The duration of grapiprant therapy depends on the underlying condition being treated and the individual patient's response. For osteoarthritis, which is a chronic and progressive condition, long-term or even lifelong treatment is often necessary to maintain comfort and mobility. Some dogs show noticeable improvement within the first week of treatment, while others may require several weeks before the full therapeutic effect becomes apparent. Periodic veterinary reassessment allows for evaluation of treatment efficacy, monitoring for adverse effects, and adjustment of the treatment plan as needed. The goal is to maintain the dog at the lowest effective dose that provides adequate pain control and quality of life.

Grapiprant should be administered orally once daily, and the manufacturer indicates that the medication can be given with or without food. However, individual dogs may tolerate the medication better when given with a small amount of food, which can help minimize any potential gastrointestinal upset. The flavored tablets are generally palatable and many dogs accept them readily, either as a treat or mixed with food. For dogs that are reluctant to take tablets, the medication can be hidden in a small amount of soft food or a commercial pill pocket. Establishing a consistent daily time for administration helps maintain steady drug levels and reduces the likelihood of missed doses.

If a dose of grapiprant is missed, it should be given as soon as the owner remembers, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular schedule resumed. Doubling up on doses to make up for missed medication is never appropriate, as this increases the risk of adverse effects without providing additional therapeutic benefit. For owners who frequently miss doses, establishing reminder systems such as phone alarms, pill organizers, or association with other daily routines can help improve compliance. Consistent dosing is important for maintaining therapeutic drug levels and optimal pain control.

Treatment should be continued for as long as recommended by the veterinarian, even if the dog appears to be feeling well. Osteoarthritis is a progressive condition, and cessation of treatment typically results in return of pain and inflammation as the medication clears from the system. However, owners should remain vigilant for any signs of adverse effects throughout treatment and contact their veterinarian if concerns arise. Regular follow-up appointments allow the veterinarian to assess treatment response, perform any necessary monitoring tests, and make adjustments to the treatment plan. Open communication between owners and veterinary staff is essential for successful long-term management of osteoarthritis with grapiprant.

Grapiprant is generally well-tolerated by most dogs when used according to veterinary instructions, and the majority of patients complete treatment courses without experiencing significant adverse effects. The targeted mechanism of action, which blocks the EP4 prostaglandin receptor rather than broadly inhibiting prostaglandin production, was designed to reduce some side effects associated with traditional NSAID therapy. However, as with all medications, grapiprant carries the potential for adverse reactions, and owners should be aware of what to watch for during treatment. Understanding the range of possible side effects enables prompt recognition and appropriate response when needed.

The most commonly reported side effects of grapiprant involve the gastrointestinal system, including vomiting, diarrhea, decreased appetite, and soft stools. In clinical trials, vomiting was the most frequently observed adverse event, occurring in a small percentage of treated dogs. These gastrointestinal effects are typically mild and often self-limiting, resolving without specific treatment or with simple supportive measures such as temporary dietary modification. Some dogs may benefit from administration with food to minimize stomach upset. While gastrointestinal effects occur less frequently with grapiprant than with some traditional NSAIDs, they remain the primary adverse events observed during therapy.

Less common side effects reported with grapiprant include lethargy, changes in drinking or urination patterns, and alterations in blood protein levels. Some dogs may appear less energetic than usual during treatment, though distinguishing medication effects from underlying disease progression can be challenging in dogs with painful conditions. Changes in thirst or urination warrant attention, as these can indicate effects on kidney function or other systemic issues. Laboratory abnormalities, including decreased serum albumin and total protein levels, have been observed in some dogs during clinical trials. Regular veterinary monitoring helps detect such changes early, allowing for appropriate management.

Serious adverse effects with grapiprant are uncommon but can occur. Gastrointestinal ulceration and bleeding, while less frequently associated with grapiprant than with traditional NSAIDs, remain possible complications. Signs of gastrointestinal bleeding include dark tarry stools, bloody vomit, pale gums, weakness, or collapse, any of which require immediate veterinary attention. Allergic reactions, characterized by facial swelling, hives, difficulty breathing, or sudden collapse, necessitate emergency care and discontinuation of the medication. Liver or kidney problems, though rare, can occur with any medication and may manifest as jaundice (yellowing of the gums or eyes), changes in urination, loss of appetite, or vomiting.

Owners should monitor their dogs closely during grapiprant therapy and report any concerning changes to their veterinarian promptly. Subtle changes in behavior, appetite, drinking habits, or elimination patterns can sometimes indicate developing problems before more obvious symptoms appear. While most dogs tolerate grapiprant well, individual variation in drug response means that some patients may experience effects not commonly seen in the general population. Maintaining communication with the veterinary team and attending scheduled follow-up appointments ensures that any issues are identified and addressed appropriately. If side effects do occur, the veterinarian can advise on whether to continue, modify, or discontinue treatment based on the severity and nature of the adverse effects.

Grapiprant should not be administered to dogs with known hypersensitivity or allergic reactions to grapiprant or any components of the Galliprant formulation. Dogs that have previously experienced adverse reactions to this medication, including symptoms such as facial swelling, hives, difficulty breathing, vomiting, diarrhea, or other concerning signs following grapiprant administration, should not receive the drug again. While cross-reactivity between grapiprant and traditional NSAIDs is not expected due to the different mechanisms of action, any history of severe drug reactions warrants careful discussion with the veterinarian before initiating any new medication.

The safety of grapiprant has not been established in dogs younger than nine months of age or weighing less than eight pounds (3.6 kg), and use in these populations is not recommended. Growing puppies have developing organ systems that may respond differently to medications than adult dogs, and the safety margins established in clinical trials did not include very young or very small animals. Breeding dogs, pregnant dogs, and lactating dogs should not receive grapiprant, as the effects on reproduction, fetal development, and nursing puppies have not been adequately studied. Owners of intact dogs intended for breeding should discuss alternative pain management options with their veterinarian.

While grapiprant's targeted mechanism of action may theoretically spare some organ functions affected by traditional NSAIDs, caution is still warranted in dogs with pre-existing liver or kidney disease. The liver is responsible for metabolizing grapiprant, and dogs with hepatic impairment may process the drug differently than healthy animals. Similarly, while grapiprant may have less impact on kidney function than COX-inhibiting NSAIDs, dogs with existing renal compromise remain at higher risk for drug-related complications. Veterinarians carefully evaluate liver and kidney function through blood work before prescribing grapiprant and may recommend more frequent monitoring in dogs with any degree of organ dysfunction.

Dogs with gastrointestinal ulceration, bleeding disorders, or conditions that predispose them to bleeding complications require careful evaluation before grapiprant is prescribed. Although the drug's mechanism suggests reduced gastrointestinal risk compared to traditional NSAIDs, complete safety in dogs with active GI disease has not been established. Dogs currently experiencing gastrointestinal bleeding or those with recent history of GI ulceration may require alternative pain management approaches. Additionally, grapiprant should be used cautiously, if at all, in dogs receiving anticoagulant therapy or those with platelet disorders, as any effects on hemostasis could be clinically significant in these patients. Complete disclosure of all health conditions and medications to the veterinarian ensures appropriate treatment selection.

Comprehensive disclosure of all medications, supplements, and over-the-counter products your dog receives is essential before starting grapiprant therapy. Drug interactions can affect medication efficacy, alter drug metabolism, or increase the risk of adverse effects. Even products that seem harmless or natural can potentially interact with prescription medications in clinically meaningful ways. The veterinarian needs a complete picture of everything the dog is receiving to assess potential interactions and develop a safe treatment plan that maximizes therapeutic benefit while minimizing risks.

The concurrent use of grapiprant with other anti-inflammatory medications requires careful consideration. While grapiprant works differently from traditional NSAIDs, combining it with COX-inhibiting drugs such as carprofen, meloxicam, or firocoxib is generally not recommended without specific veterinary guidance, as the anti-inflammatory effects may be additive and could increase the risk of adverse events. Similarly, combining grapiprant with corticosteroids such as prednisone or dexamethasone warrants caution, as both drug classes affect inflammatory processes and their combined use could potentiate adverse effects, particularly on the gastrointestinal system. If switching between anti-inflammatory medications, appropriate washout periods should be observed.

Grapiprant is highly bound to plasma proteins, which creates the potential for interactions with other highly protein-bound medications. When two highly protein-bound drugs are administered together, they may compete for binding sites, potentially increasing the free (active) concentration of one or both drugs and altering their effects. Medications that share this characteristic include certain antibiotics, cardiac drugs, and other commonly used veterinary medications. The clinical significance of such interactions depends on the specific drugs involved and patient factors. Veterinarians consider protein binding when evaluating potential drug combinations and may adjust doses or increase monitoring accordingly.

Dietary supplements commonly given to dogs with osteoarthritis, such as glucosamine, chondroitin, and fish oil, do not have known clinically significant interactions with grapiprant and are often used concurrently as part of a multimodal approach to joint health. However, all supplements should be disclosed to the veterinarian, as some products may have unexpected effects or contamination issues. Herbal supplements and alternative therapies should be specifically discussed, as some botanical products have anti-inflammatory or anticoagulant properties that could potentially interact with grapiprant. The growing use of CBD products in pets also warrants disclosure, as the interactions between cannabinoids and various medications are still being characterized.

Food interactions with grapiprant are minimal, and the medication can be administered with or without food according to the manufacturer's guidelines. However, high-fat meals may affect the absorption of some medications, and consistency in administration conditions helps maintain predictable drug levels. Dogs receiving multiple medications should have their dosing schedules coordinated to minimize potential interactions and maximize compliance. Any changes to a dog's medication regimen during grapiprant therapy should prompt communication with the prescribing veterinarian, who can assess whether adjustments to grapiprant dosing or monitoring are needed.

General precautions for grapiprant use begin with proper patient selection and appropriate veterinary oversight throughout treatment. The medication should only be used in dogs for which it has been specifically prescribed after veterinary examination and assessment. Owners should not share grapiprant between pets, use leftover medication from previous prescriptions, or adjust doses without veterinary guidance. Accurate weight measurement is essential for proper dosing, and dogs should be weighed on a reliable scale before each prescription. Following the prescribed dosing schedule and reporting any difficulties with administration helps ensure optimal treatment outcomes.

While grapiprant's mechanism of action does not involve the same pathways affected by the MDR1 (ABCB1) gene mutation that impacts certain herding breeds' response to some medications, responsible medication use in all dogs includes awareness of breed-specific considerations. Herding breeds such as Collies, Australian Shepherds, Shetland Sheepdogs, and Border Collies have higher prevalence of drug sensitivities related to the MDR1 mutation, although this primarily affects different drug classes than grapiprant. Nonetheless, owners of herding breeds should inform their veterinarian of their dog's breed heritage, and any unusual reactions or sensitivities should be reported and evaluated. Genetic testing can provide definitive information about a dog's MDR1 status.

Environmental and handling precautions help ensure safe medication use in multi-person and multi-pet households. Grapiprant tablets should be stored securely out of reach of children and other pets. While the tablets are less likely to be sought out by dogs compared to highly palatable chewable medications, accidental ingestion remains a concern, particularly in households with dogs prone to counter-surfing or getting into forbidden areas. Medication should never be left unattended where pets or children could access it. Standard hygiene practices, such as hand washing after handling medication, are sufficient for human handlers.

Monitoring requirements during grapiprant therapy include both owner observations at home and veterinary assessment through periodic examinations and laboratory testing. Owners should watch for changes in appetite, water consumption, urination patterns, stool quality, energy level, mobility, and behavior. Any vomiting, diarrhea, lethargy, or signs of gastrointestinal distress should be noted and reported. Veterinary monitoring typically includes periodic blood work to assess liver and kidney function and check blood protein levels, particularly for dogs on long-term therapy. The frequency of monitoring depends on the individual patient's health status, concurrent medications, and duration of treatment.

Special patient populations require additional consideration when grapiprant is prescribed. Geriatric dogs, who represent a significant proportion of patients with osteoarthritis, may have age-related changes in organ function that affect drug metabolism and increase susceptibility to adverse effects. While grapiprant may be better tolerated than traditional NSAIDs in some senior patients, careful monitoring remains essential. Dogs with concurrent health conditions, particularly cardiac, renal, or hepatic disease, require thorough evaluation of benefit-risk considerations. Dogs receiving other medications need assessment for potential interactions. Working dogs and canine athletes may mask pain signals while on medication, potentially leading to overexertion; appropriate activity restrictions should be discussed with the veterinarian.

Proper storage of grapiprant tablets maintains medication efficacy and prevents accidental ingestion by pets or children. Galliprant tablets should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit (20 to 25 degrees Celsius), with brief excursions permitted to temperatures between 59 and 86 degrees Fahrenheit (15 to 30 degrees Celsius). The medication should be kept in its original container with the child-resistant cap secured between uses. Storage areas should be dry and protected from excessive humidity, which could affect tablet integrity. Avoid storing the medication in locations subject to temperature extremes, such as bathrooms, kitchens near stoves, cars, or areas with direct sunlight.

Secure storage is essential to prevent accidental ingestion by household pets or children. While Galliprant tablets are not as highly palatable as some beef or pork-flavored chewable medications, dogs may still consume them if given the opportunity, potentially resulting in overdose and serious adverse effects. Medication should be stored in cabinets or containers that are inaccessible to pets and children. Child-resistant packaging provides some protection but should not be considered sufficient safeguarding against determined pets that can chew through containers. Never leave medication bottles or loose tablets on counters, tables, or other accessible surfaces, even briefly during administration to your pet.

Proper disposal of unused, unwanted, or expired grapiprant protects both household members and the environment. The preferred disposal method is through authorized drug take-back programs, which are offered by many pharmacies, veterinary clinics, and community organizations. These programs ensure medications are destroyed safely and do not enter the water supply or ecosystem. If take-back programs are not available in your area, the FDA recommends mixing medications with an undesirable substance such as used coffee grounds, dirt, or cat litter, sealing the mixture in a container, and disposing of it in household trash. Remove or obscure any personal information from medication packaging before disposal. Expired medications should not be administered to pets, as the drug may have degraded, potentially affecting both safety and efficacy. Regularly checking medication expiration dates and properly disposing of outdated products helps maintain a safe home environment.

Grapiprant is generally well-tolerated across the diverse range of dog breeds when appropriately prescribed and administered. The enormous variation in canine body size, from toy breeds weighing just a few pounds to giant breeds exceeding 150 pounds, primarily affects dosing calculations rather than fundamental drug safety or efficacy. Veterinarians consider breed-related factors alongside individual patient characteristics when prescribing grapiprant, and owners should ensure their veterinarian is fully aware of their dog's breed background, including any mixed breed heritage that might influence drug response or disease predisposition.

Certain breed-specific health predispositions warrant consideration in the context of grapiprant therapy. Breeds with increased risk of kidney disease, such as English Cocker Spaniels, Bull Terriers, and Cavalier King Charles Spaniels, may benefit from enhanced monitoring of renal function during treatment. Breeds prone to liver disease should similarly receive appropriate hepatic monitoring. While grapiprant's targeted mechanism may offer theoretical advantages over traditional NSAIDs for organ protection, individual patient factors remain important regardless of the medication chosen. Breeds predisposed to gastrointestinal conditions may still experience GI-related side effects, and owners should remain vigilant for any digestive disturbances during treatment.

Size-related considerations significantly impact grapiprant dosing and administration across the breed spectrum. Giant breeds such as Great Danes, Irish Wolfhounds, Mastiffs, and Saint Bernards require larger doses, which may involve multiple tablets and increased medication costs over the course of long-term therapy. These breeds also tend to develop osteoarthritis at younger ages due to the mechanical stresses on their joints, potentially requiring earlier intervention with pain management. Conversely, very small dogs approaching the minimum weight threshold for grapiprant use present dosing precision challenges. The 20 mg tablets serve smaller dogs, but those below eight pounds are not appropriate candidates for grapiprant therapy due to lack of established safety data in this population.

Age considerations intersect with breed characteristics in osteoarthritis management. Large and giant breed dogs are often considered senior at younger chronological ages than small breeds, with some giant breeds entering their senior years as early as five to six years of age. This means that large breed dogs may require osteoarthritis management, including grapiprant therapy, for a longer proportion of their lives than small breeds that don't develop significant joint disease until their teenage years. The earlier onset of degenerative joint disease in large breeds also raises considerations about cumulative drug exposure during extended therapy. Conversely, small breed dogs tend to live longer and may ultimately require more years of treatment despite later disease onset. Regardless of breed or size, regular veterinary monitoring during chronic grapiprant therapy ensures that treatment remains appropriate and safe over time.

Several veterinary-approved NSAIDs serve as alternatives to grapiprant for managing osteoarthritis pain in dogs. Traditional COX-inhibiting NSAIDs include carprofen (Rimadyl), meloxicam (Metacam), firocoxib (Previcox), and deracoxib (Deramaxx), all of which have established efficacy for canine osteoarthritis and postoperative pain. These medications work by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin production throughout the body. While effective for pain management, their broader mechanism of action may carry higher risk of certain side effects compared to grapiprant's targeted approach. The choice between grapiprant and traditional NSAIDs depends on individual patient factors, previous treatment responses, cost considerations, and veterinary assessment of the most appropriate option for each situation.

When NSAID therapy is not suitable or when additional pain control is needed, alternative medication classes may be employed. Gabapentin is commonly used for chronic pain management, particularly for neuropathic components of pain, and can sometimes be combined with grapiprant for multimodal analgesia. Amantadine is another adjunctive medication that may enhance pain control when NSAIDs alone are insufficient. For dogs that cannot receive any oral anti-inflammatory medications, newer biologic therapies such as bedinvetmab (Librela), a monoclonal antibody targeting nerve growth factor, offer monthly injection-based pain management. Tramadol, though its efficacy in dogs has been questioned by recent research, is still sometimes prescribed. Corticosteroids provide potent anti-inflammatory effects but are generally not combined with grapiprant and carry significant side effects with long-term use.

Complementary approaches often support medication therapy for optimal management of canine osteoarthritis. Joint supplements containing glucosamine, chondroitin, and omega-3 fatty acids are commonly recommended alongside grapiprant or other pain medications. Weight management is crucial for dogs with joint disease, as excess body weight places additional mechanical stress on already compromised joints. Physical rehabilitation, including therapeutic exercises, hydrotherapy, and professional manual therapy, can improve strength, range of motion, and overall function. Environmental modifications such as orthopedic bedding, ramps to avoid stairs, raised food and water bowls, and non-slip floor surfaces support dogs with mobility limitations. Acupuncture and laser therapy are increasingly offered as adjunctive treatments. All changes to a dog's treatment plan, including the addition of supplements or complementary therapies, should be discussed with the prescribing veterinarian to ensure safety and coordination of care.